Preliminary 5-year Survival: Continuous Tafamidis Versus Placebo to Tafamidis10
- Preliminary 5-year survival rate was 53.2% in the continuous tafamidis group and 32.4% in the placebo to tafamidis group
- There was no significant interaction of treatment with genotype (P=0.58) or NYHA baseline classification (P=0.73)
Preliminary 5-year Survival Rate by Genotype
| Continuous tafamidis | Placebo to tafamidis | |
|---|---|---|
| ATTRwt-CM KM preliminary estimates of 5-year survival (%) |
57.8 | 36.3 |
| ATTRv-CM KM preliminary estimates of 5-year survival (%) |
39.1 | 20.9 |
Preliminary 5-year Survival Rate by NYHA Class
| Continuous tafamidis | Placebo to tafamidis | |
|---|---|---|
| NYHA Class I and Class II KM preliminary estimates of 5-year survival (%) |
61.4 | 40.3 |
| NYHA Class III KM preliminary estimates of 5-year survival (%) |
35.0 | 18.0 |
ATTR-ACT: Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTRv-CM: hereditary transthyretin amyloid cardiomyopathy; ATTRwt-CM: wild-type transthyretin amyloid cardiomyopathy; KM: Kaplan Meier; LTE: long-term extension; NYHA: New York Heart Association.
